News & Topics

HOME > News & Topics > Research > FY 2018 > Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors (Kumanogoh group in Sci Rep)

Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors (Kumanogoh group in Sci Rep)

Takayuki Shiroyama (Oncology Center of Osaka University Hospital), Atsushi Kumanogoh (Graduate School of Medicine, Osaka University/IFReC) and the research group showed that sarcopenia at baseline as determined using computed tomography is a significant predictor of worse outcome in patients with advanced NSCLC receiving PD-1 blockade.

Press Release 20190222 Figure: Evaluation of muscle mass by abdominal CT.
The large psoas muscle is shown in green.
The muscle mass is sufficient (L), whereas the mass decrease (R).

Commentary(PDF)


Article (External Link)


Contact:
Atsushi Kumanogoh

Atsushi Kumanogoh(Immunopathology)


Tel+81-6-6879-3831
Mailkumanogoimed3.med.osaka-u.ac.jp

Immunology Frontier Research Center, Osaka University (WPI-IFReC)

Archives

 
TOPに戻る